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Conclusions: Performed measurements were shown the similar as for 
rectum detector angular dependence of IN-VIVO bladder detector 
readings for Ir-192 radiation. Results make obvious that for more 
accurate probe calibration the angular testing of its sensitivity should 
be done. Angular and off-axial components of the diode response 
should be identified. The best angular ranges for performing the long-
term reproducibility calibrations should be recognized and appropriate 
marking on the catheter surface should be done. The fluoroscopic 
images, which are taken during treatment planning procedure, allow 
to find out the angle of the detector to direction of radiation coming 
from the radiation source and based on that appropriate correction 
factor can be estimated. As the final result of all these actions it can 
be achieved more agreement between planning treatment dose 
calculations and IN-VIVO measurements. 
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Purpose/Objective: Volumetric modulated arc radiotherapy (VMAT) or 
Rapid Arc (RA) is being widely used for highly conformal dose 
distribution and faster treatments as well. It is a system for intensity-
modulated radiotherapy treatment (IMRT) delivery that achieves high 
dose conformality by optimizing the dose rate, gantry speed, and the 
leaf positions of the dynamic multileaf collimator (DMLC). Stringent 
dosimetric verification is required for accurate delivery of planned 
dose from the treatment planning system (TPS). Recently, a novel 
ISORADTM (Sun Nuclear, USA)cylindrical diode was procured and the 
objective of this study was to perform the rapid arc patient-specific 
dosimetry with this diode. 
Materials and Methods: RapidArc patient-specific dosimetry was 
carried out for eight patients (n = 8) with carcinoma of prostate. All 
the patients were planned on Eclipse (8.6.1, Varian,USA) TPS with 6 
MV x-rays from a dual energy Novalis Tx linear accelerator (Varian, 
USA). A single arc was used for all the patients. Progressive Resolution 
Optimization (PRO) and Analytical Anisotropic Algorithm (AAA) were 
used for arc optimization and dose calculation respectively. 
Verification plan was generated in Eclipse for all the patients. For 
this, a solid water slab phantom (30 cm x 30 cm x 30 cm) with ISORAD 
diode was scanned in computed tomography (CT) machine (GE, USA). 
A separate indigenous adaptor was designed and fabricated for this 
diode to be used in these slabs. The dose was calculated at central 
axis and was noted. The same setup was simulated on linac and dose 
was measured at the isocentre. All measurements were compared 
with theTPS dose calculation via absolute point dose comparison. The 
film and ion chamber results were similarly compared with the ion 
chamber (FC65G, IBA, Sweden) measurements as well. Prior to this, 
the diode was calibrated against a reference ionization chamber at 
the same depth and the diode sensitivity correction was determined.  
Results: The diode readings were reproducible and the sensitivity 
correction factor was 1.10. Absolute point dose measurements agreed 
well with treatment planning system computed doses (ion chamber: 
mean deviation,1.2%, range, -0.5% to 2.9%; ISORAD: mean deviation, 
0.3%, SD 1.6, range, -0.4%to 2.8%). The institutional dosimetry 
acceptance criterion for IMRT/VMAT is ±3%. 
Conclusions: For pre-treatment plan verification of advanced 
treatment techniques volumetric modulated arc therapy, a fast and 
reliable dosimetric device is required. In this study, we investigated 
the suitability of ISORAD for verification of Rapidarc therapy plans. 
The measurements and dosimetry proves that ISORAD can be used for 
quantifying absolute dose as an alternative to ion chamber 
measurement. However, ion chamber measurements are 
recommended for absolute dose comparison. Moreover, this diode was 
found useful due to its cylindrical shape an ease of setup. 
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Purpose/Objective: To develop a protocol (irradiation procedure, 
action levels) for an external quality control of stereotactic beams of 
Cyberknife® with Equal-Estro laboratory. These preliminary studies 
involved seven French institutions. 
Materials and Methods: Equal-Estro provided a cubic water-
equivalent plastic phantom (so-called'mini-cube') containing four 
thermoluminescent detectors, TLDs, (TLD-100, Harshaw) and three 
radiochromic films (Gafchromic EBT2). This phantom was designed to 
be inserted in ananthropomorphic head phantom used to perform end-
to-end quality controls. The phantom had to be irradiated according 
to a protocol describing a target volume in which three TLDs were 
encompassed with a 5mm isotropic margin, and one organ at risk 
represented by the fourth TLD. A maximum dose of 4.1Gy was 
prescribed to the target volume. After irradiation in a single fraction, 
the 'mini-cube' phantom was returned to Equal-Estro laboratory to be 
analyzed and measured doses were compared to calculated doses. 
Absolute dose deviations were evaluated using the TLDs and gamma-
index analyses were performed on films. A preliminary study was 
performed to determine the statistical accuracy and the most 
appropriate action levels to be applied to all tests.  
Results: Intrinsic TLD dose measurement on Cyberknife beams is 
reliable as reproducibility was of about 1.7% (1 SD) for a single beam. 
Dose deviations were lower than 5% for PTV-TLDs in most of the tested 
centers but larger deviations were observed on the OAR-TLD in some 
institutions. Investigations performed subsequently have identified the 
non homogeneous dose distribution onthe TLD to be the main cause of 
measured deviations. Analyses of different gamma-index criteria 
allowed choosing the 5%/2mm as the most appropriate tolerance level 
for gamma index tests, which is consistent with the film analysis 
procedure uncertainty (mostly due to the matching uncertainty of 
dose distributions). 
Conclusions: An accuracy of 5% can be achieved if dose 
inhomogeneity in TLDs volumes is reduced in the planning process. 
The final version of the planning protocol will include the use of a PTV 
and a PRV around the TLDs, with constraints on dose homogeneity on 
the DVHs. This work will be followed by a second round of irradiations 
using the improved version of the procedure. 
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Purpose/Objective: The aim of this work is to characterize the Dosi-
Secure® detector for in vivo dosimetry in High Energy photon beams. 
Measurements are first performed on phantom and then on patients to 
determine the level of accuracy of the device in clinical use. 
Materials and Methods: TheDosi-Secure® system consists of a wireless 
and passive detector (Dosi-Patch®), a tactile reader (Dosi-Pad®) and 
an associated software. This system ensures the traceability of in vivo 
dosimetry for each patient during the radiotherapy session. The 
detector is based on a specific PMOS technology. A build-up cap is 
incorporated to allow measurements at the maximum depth dose 
(entrance dose). The dosimeters are calibrated by the manufacturer; 
there have no embedded correction factors. The dosimeters are 
placed on the surface of a water equivalent slab phantom and 
irradiated with 8MV and 25MV photon beams. The influence of the 
variation of different parameters on detector response is evaluated: 
field size (open and wedged beams), SSD and angular incidence. All 
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the measurements were compared to the dose measured with a 
cylindrical ionization chamber placed at the maximum depth dose. 
Repeatability over 10 measurements is also investigated. The device 
accuracy in clinical use is assessed by performing measurements of 
clinical beams on anthropomorphic phantoms (8-25MV) and on 
patients (25MV). Results arecompared with entrance dose obtained 
with the TPS. 
Results: Dosi-Patch® has the same behavior as the ionization chamber 
for varying field size with and without wedge (EDW 60°). Agreement is 
good with a deviation less than 5% for both energies. There is no 
angular dependence in both energies (in the range ±30°). Dosi-Patch® 
overestimates the dose for short SSD. The deviation increases up to 
7.5% (8MV) and 4.9% (25MV) as the SSD decreases. This effect is more 
pronounced for 8MV than 25MV. This suggests a need for SSD 
correction for 8MV. The measurements repeatability is correct with a 
coefficient of variation of 0.4% for 8MV and 0.44% for 25MV. Results of 
clinical beams measurements on phantom and on patients are 
presented in figure1. 90% of the measurements on phantom for 8MV 
(with SSD correction) have a deviation ≤ 5% compared to the TPS. For 
25MV photon beam, 83% of the measurements on phantom and 84% of 
the measurements on patients have a deviation ≤ 5%. 
For all measurements with a deviation more than ± 5%, the difference 
in absolute dose is less than 10 cGy, which is suitable for an in vivo 
dosimetry use. 
 
Figure 1:Distribution of the deviations between Dosi-Patch® and TPS 
measurements (n=20,29,19 for Phantom 8MV,25MV and Patients 25MV 
respectively) 
 
Conclusions: Dosi-Secure® is an accurate detector for in vivo 
dosimetry in 8MV and 25MV photon beams. There is no need for 
correction factors for varying field size and angle. However, the use 
of correction factor for SSD improves the accuracy of the detector. 
Measurements on patients with SSD correction factor in 8MV photon 
beams are currently implemented. 
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Purpose/Objective: For multi leaf collimator (MLC) calibration 
Electronic Portal Image Devices (EPIDs) are replacing film based 
methods. A systematic error can be introduced if the field size 
measured with the EPID differs from the field size of the reference 
field size. The reference field size (at a depth of 10 cm in water and 
at a source distance of 100 cm) is measured using radiochromic film 
(Gafchromatic EBT2), since its electron density is close to that of 
water. We observed a small systematic deviation in the field size 
measured with an EPID compared to film. The aim of this study is to 
minimize this systematic error in the field size. 
Materials and Methods: All measurements are performed on an 
Axesse linac (Elekta, Stockholm, Sweden) equipped with an IviewGT 
EPID. This EPID basically consists of a 1 mm thick copper plate with a 
scintillator screen. The flat panel detector has a size of 40.96 × 40.96 
cm2 and has 10242 pixels. The source to scintillator distance is 159.7 
cm. The resulting pixel size at isocenter is 0.251 mm. The field size is 
defined as the width at half the dose of the field center. All 
measurements are performed 10 times for 6 MV photon beams. The 
first part of this study consist of measuring a nominal field size of 4 x 
4 cm². EPID measurements are performed with additional plates of 
polymethylmethacrylaat (PMMA) on top of the copper plate of the 
EPID. The thickness of PMMA is converted into Water Equivalent 
Thickness (WET) using a factor 1.137. The second part consists of leaf 
calibration measurements. The leaf calibration consists of a strip test 
with nine adjacent segments of 2 cm wide, separated by 1 mm and 
exposed on the EPID. Normally the leaf calibration is performed with 
the standard EPID configuration. In this study the leaf calibration is 
also performed using an additional build-up of 2.5 mm copper (WET ~ 
2.2 cm) and with an additional build-up of PMMA with a WET of 8.5 
cm. 
Results: The effect of additional build-up on the field size is depicted 
in Figure 1. The build-up is expressed as water equivalent thickness 
added on the EPID. 
 
 Figure 1. The effect of additional build-up on the field size. 
The field size measured with EPID without additional build-up is 
approximately 0.2 mm smaller than the reference field size. 
Performing a leaf calibration adding 2.5 mm copper yields a field size 
close to the reference field size. 
Conclusions: The leaf calibration with an unmodified EPID causes a 
systematic deviation of the measured field size of approximately 0.2 
mm. Using an additional build-up of 2.5 mm copper on the EPID the 
measured field size is in excellent agreement with the expected field 
size at reference depth in water. Adding this extra copper has no 
clinical relevant effect on image quality (van Elmpt et al., 2008). This 
modification is therefore recommended for all EPIDs used for MLC 
calibrations. 
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Purpose/Objective: The daily quality controls (QC) of Intensity 
Modulated Radiotherapy Treatments (IMRT) are part ofthe 
radiotherapy chain, leading to a significant drain of human resources. 
The aim of this study is determine whether they are still necessary for 
every single patient. In our clinical routine we perform two 
measurements prior to the first fraction of treatment. One point dose 
measurement and one planar dose measurements by matrix of 
ionization chambers. We analyzed the results of pre-treatment 
measurement checks to quantify the occurrence of results out of 
tolerance, and analyze the causes of failure. 
Materials and Methods: We analyzed 544 pre-planning checks 
performed in 19 months of Tomotherapy activity. All analyzed 
measurements were performed with an Exradin micro-ionization 
chamber (A1SL), a water equivalent cheese phantom provided by the 
Tomotherapy Accuray™. Each treatment plan is re-calculated on a CT 
image of cheese phantom with the ion chamber to determinate the 
dose in a RT treatment high dose point. All measurements were 
corrected for daily output variation. We analyzed our measurements 
comparing them to calculated dose. The tolerance for this test is 3% 
of measured versus calculated dose. 
Results: Figure 1 reports the absolute frequency of dose difference 
results 
